Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A, Motro M, Fisman EZ
Cardiovasc Diabetol 2005, 4:14
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Review    
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease
Fisman EZ, Tenenbaum A
Cardiovascular Diabetology 2009, 8:38 (20 July 2009)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles] [1 comment]
2.


Original investigation    
Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
Tenenbaum A, Boyko V, Fisman EZ, Goldenberg I, Adler Y, Feinberg MS, Motro M, Tanne D, Shemesh J, Schwammenthal E, Behar S
Cardiovascular Diabetology 2008, 7:18 (19 June 2008)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
3.


Hypothesis    
Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OABSM
Cardiovascular Diabetology 2008, 7:6 (20 March 2008)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
4.


Review    
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
Tenenbaum A, Fisman EZ, Motro M, Adler Y
Cardiovascular Diabetology 2006, 5:20 (26 September 2006)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]

This article is also cited by a further 4 articles in PubMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.